NCT01919086 2026-03-02
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
Clinical Trials
301 trialsNCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT01745640 2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2 Completed
NCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed
NCT02969837 2026-01-16
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT02441686 2026-01-13
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02412228 2025-10-15
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Brown University
Phase 2 Completed
NCT03731832 2025-09-30
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
GWT-TUD GmbH
Phase 2 Completed
NCT04045795 2025-09-12
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Sanofi
Phase 1 Completed
NCT01745588 2025-09-11
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01415882 2025-09-05
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Phase 2 Completed
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT03934684 2025-08-06
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT01711671 2025-08-03
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Leap Therapeutics, Inc.
Phase 1 Completed
NCT06163040 2025-07-31
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT04813653 2025-07-24
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
Tel-Aviv Sourasky Medical Center
Phase 1 Completed
NCT02765854 2025-06-26
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
Phase 2 Completed
NCT03713294 2025-06-24
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT03012880 2025-06-04
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03158688 2025-05-09
CANDOR
Amgen
Phase 3 Completed
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02224729 2025-04-30
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Thomas Jefferson University
Phase 2 Completed
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT03860038 2025-04-24
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ Biopharma Co., Ltd.
Phase 2 Completed
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
NCT02649790 2025-03-19
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
Phase 1/2 Completed
NCT03544281 2025-03-18
DREAMM 6
GlaxoSmithKline
Phase 1/2 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT02918331 2025-02-03
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT02990338 2025-01-17
ICARIA-MM
Sanofi
Phase 3 Completed
NCT03773107 2025-01-13
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Completed
NCT01903811 2024-12-20
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT00482261 2024-11-08
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01091831 2024-11-06
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT03399539 2024-11-04
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
Mayo Clinic
Phase 1 Completed